Published in J Hepatol on January 01, 2003
Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer (2010) 1.92
Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer (2005) 1.51
Diagnosis of hepatocellular carcinoma. World J Gastroenterol (2009) 1.39
Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol (2009) 1.33
Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci (2007) 1.31
Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol (2009) 1.31
Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol (2008) 1.28
Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol (2005) 1.22
Diffusion-weighted PROPELLER MRI for quantitative assessment of liver tumor necrotic fraction and viable tumor volume in VX2 rabbits. J Magn Reson Imaging (2008) 1.08
Hepatocellular carcinoma in the world and the middle East. Middle East J Dig Dis (2010) 1.07
Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res (2009) 1.02
Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol (2010) 1.02
Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. Eur Radiol (2006) 0.96
Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol (2003) 0.96
Assessing liver tumor stiffness by transient elastography. Hepatol Int (2007) 0.93
Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. Acta Pharmacol Sin (2010) 0.92
Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol (2009) 0.89
Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci (2008) 0.88
Causes of death in patients with unresectable hepatocellular carcinoma. Dig Dis Sci (2007) 0.88
Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol (2010) 0.87
Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol (2013) 0.86
First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). Int J Oncol (2012) 0.86
Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer (2007) 0.84
Etiology and Viral Genotype in Patients with End-Stage Liver Diseases admitted to a Hepatology Unit in Colombia. Hepat Res Treat (2011) 0.84
Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway. PLoS One (2012) 0.83
Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis--a randomized study. World J Surg (2006) 0.83
Alcohol and HCV chronic infection are risk cofactors of type 2 diabetes mellitus for hepatocellular carcinoma in Italy. Int J Environ Res Public Health (2010) 0.82
Hepatocellular carcinoma--rising incidence, changing therapeutic strategies. Wien Med Wochenschr (2006) 0.82
CEACAM1 long cytoplasmic domain isoform is associated with invasion and recurrence of hepatocellular carcinoma. Ann Surg Oncol (2014) 0.79
Developments in liver transplantation. Gut (2004) 0.79
Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005). World J Gastroenterol (2007) 0.79
Medical treatment of hepatocellular carcinoma. Mediterr J Hematol Infect Dis (2009) 0.79
Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol (2007) 0.78
Role of CD44 expression in non-tumor tissue on intrahepatic recurrence of hepatocellular carcinoma. Int J Clin Oncol (2012) 0.78
Calcium signaling in the liver. Compr Physiol (2013) 0.78
Expression of cytochrome P4502E1 gene in hepatocellular carcinoma. World J Gastroenterol (2004) 0.78
Chemoembolization with drug-eluting beads complicated by intrahepatic biloma. Semin Intervent Radiol (2011) 0.77
Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. Nanomedicine (2016) 0.77
RMP predicts survival and adjuvant TACE response in hepatocellular carcinoma. Oncotarget (2015) 0.77
Use of magnetic resonance elastography for assessing liver functional reserve: A clinical study. World J Gastroenterol (2015) 0.77
The cooperative effect of p53 and Rb in local nanotherapy in a rabbit VX2 model of hepatocellular carcinoma. Int J Nanomedicine (2013) 0.77
Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma. PLoS One (2016) 0.76
HCV infection-associated hepatocellular carcinoma in humanized mice. Infect Agent Cancer (2015) 0.76
[Hepatocellular carcinoma in rural Burkina Faso Africa: contribution of ultrasound, about 58 cases]. Pan Afr Med J (2010) 0.76
Minnelide, a novel drug for pancreatic and liver cancer. Pancreatology (2015) 0.75
Obesity Does Not Influence Outcomes in Hepatocellular Carcinoma Patients following Curative Hepatectomy. PLoS One (2015) 0.75
Association between PNPLA3 rs738409 polymorphisms and risk of hepatocellular carcinoma and its development in patients with cirrhosis: a meta-analysis. Int J Clin Exp Med (2015) 0.75
Metastatic carcinoma of the oral region: An analysis of 21 cases. Med Oral Patol Oral Cir Bucal (2017) 0.75
Medical Care of the Patient With Compensated Cirrhosis. Gastroenterol Hepatol (N Y) (2006) 0.75
Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma. Curr Oncol (2016) 0.75
Hepatitis viruses exploitation of host DNA methyltransferases functions. Clin Exp Med (2015) 0.75
Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol (2003) 9.19
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology (2005) 5.93
Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol (2006) 3.57
Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology (2006) 3.19
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology (2009) 3.01
Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab (2011) 2.48
Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol (2006) 2.44
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology (2006) 2.21
Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int (2008) 2.19
Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology (2011) 2.14
Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol (2008) 2.05
Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. Eur J Gastroenterol Hepatol (2005) 1.94
Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr (2006) 1.87
Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut (2010) 1.80
Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol (2010) 1.70
Telomerase gene mutations are associated with cirrhosis formation. Hepatology (2011) 1.67
Survival after radiofrequency ablation and salvage transplantation in patients with hepatocellular carcinoma and Child-Pugh A cirrhosis. J Hepatol (2011) 1.46
Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol (2007) 1.31
Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology (2007) 1.31
ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology (2008) 1.20
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer (2010) 1.15
Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta (2007) 1.14
Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clin Cancer Res (2012) 1.10
Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol (2006) 1.09
Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol (2008) 1.09
PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol (2012) 1.06
Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Virol (2006) 1.06
Large (>or=5.0-cm) HCCs: multipolar RF ablation with three internally cooled bipolar electrodes--initial experience in 26 patients. Radiology (2008) 1.04
Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol (2007) 1.02
Metabolomic approach by 1H NMR spectroscopy of serum for the assessment of chronic liver failure in patients with cirrhosis. J Proteome Res (2011) 0.97
ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. J Hepatol (2013) 0.95
Genetic polymorphisms in antioxidant enzymes modulate hepatic iron accumulation and hepatocellular carcinoma development in patients with alcohol-induced cirrhosis. Cancer Res (2006) 0.94
Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology (2009) 0.93
Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev (2013) 0.93
Intrasinusoidal cytotoxic CD8+ T cells in nodular regenerative hyperplasia of the liver. Hum Pathol (2004) 0.92
Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. Cancer Prev Res (Phila) (2012) 0.91
Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol (2010) 0.89
Intermediate hepatobiliary cells predict an increased risk of hepatocarcinogenesis in patients with hepatitis C virus-related cirrhosis. Gastroenterology (2010) 0.89
Genetic dimorphism in superoxide dismutase and susceptibility to alcoholic cirrhosis, hepatocellular carcinoma, and death. Clin Gastroenterol Hepatol (2005) 0.89
Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol (2008) 0.89
Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology (2009) 0.87
Relationships between fibrosis amounts assessed by morphometry and liver stiffness measurements in chronic hepatitis or steatohepatitis. Eur J Gastroenterol Hepatol (2009) 0.86
Cytolytic hepatitis possibly related to levonorgestrel/ethinylestradiol oral contraceptive use: 2 case reports. Ann Pharmacother (2010) 0.84
Chemokine RANTES promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virus-related cirrhosis. Cancer Epidemiol Biomarkers Prev (2011) 0.83
Liver stiffness measurement versus clinicians' prediction or both for the assessment of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol (2006) 0.83
Liver stiffness measurement in patients with cirrhosis and hepatocellular carcinoma: a case-control study. Eur J Gastroenterol Hepatol (2009) 0.83
Large infiltrative hepatocellular carcinomas: treatment with percutaneous intraarterial ethanol injection alone or in combination with conventional percutaneous ethanol injection. Radiology (2004) 0.82
[Fibroscan: instructions for use]. Gastroenterol Clin Biol (2006) 0.82
Transient elastography in non-alcoholic fatty liver disease. Ann Hepatol (2012) 0.82
Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study. Eur J Gastroenterol Hepatol (2007) 0.81
Significance of hepatitis B virus genotypes A to E in a cohort of patients with chronic hepatitis B in the Seine Saint Denis District of Paris (France). J Med Virol (2006) 0.81
Ethanol versus radiofrequency ablation for the treatment of small hepatocellular carcinoma in patients with cirrhosis: a retrospective study of efficacy and cost. Gastroenterol Clin Biol (2006) 0.81
Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma. World J Gastroenterol (2008) 0.81
Radiofrequency ablation for the treatment of liver tumors in the caudate lobe. J Vasc Interv Radiol (2005) 0.81
Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver Int (2008) 0.80
[Hepatitis C virus screening in drug users in an addiction out-patient unit]. Gastroenterol Clin Biol (2002) 0.80
Serum albumin and platelet count but not portal pressure are predictive of death in patients with Child-Pugh A hepatitis C virus-related cirrhosis. Gastroenterol Clin Biol (2005) 0.80
Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases: epidemiology and histopathology of distant nontumoral liver in 57 White patients. Eur J Gastroenterol Hepatol (2013) 0.80
A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis. J Hepatol (2011) 0.80
Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease. World J Gastroenterol (2007) 0.79
Manganese superoxide dismutase dimorphism and iron overload, hepatocellular carcinoma, and death in hepatitis C virus-infected patients. Clin Gastroenterol Hepatol (2007) 0.79
Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatment-Long-term Results. Radiology (2016) 0.78
How to assess liver fibrosis and for what purpose? J Hepatol (2006) 0.78
Keratin 8 variants are infrequent in patients with alcohol-related liver cirrhosis and do not associate with development of hepatocellular carcinoma. BMC Gastroenterol (2012) 0.77
Diaphragmatic necrosis after radiofrequency ablation of hepatocellular carcinoma: a successful surgical repair. Clin Res Hepatol Gastroenterol (2012) 0.77
Radiofrequency ablation with internally cooled versus perfused electrodes for the treatment of small hepatocellular carcinoma in patients with cirrhosis. J Vasc Interv Radiol (2008) 0.77
Do genetic variations in antioxidant enzymes influence the course of hereditary hemochromatosis? Antioxid Redox Signal (2010) 0.77
Liver angiogenesis as a risk factor for hepatocellular carcinoma development in hepatitis C virus cirrhotic patients. World J Gastroenterol (2007) 0.77
Is there an ideal prognostic classification for hepatocellular carcinoma? The quest for the Holy Grail. J Hepatol (2010) 0.76
[Practical screening and early treatment of hepatocellular carcinoma. Results of a French survey]. Gastroenterol Clin Biol (2002) 0.76
Severe hepatitis induced by cyproterone acetate: role of corticosteroids. A case report. Ann Hepatol (2013) 0.76
The manganese superoxide dismutase Ala16Val dimorphism modulates iron accumulation in human hepatoma cells. Free Radic Biol Med (2008) 0.76
A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg (2011) 0.75
Interventional radiology as a fine art. J Hepatol (2007) 0.75
Stakeholder perspectives on European priorities for comprehensive liver cancer control: a conjoint analysis. Eur J Public Health (2013) 0.75
High frequency of X chromosome abnormalities in women with short stature and elevated liver enzymes. J Clin Endocrinol Metab (2014) 0.75
[Percutaneous ablation of hepatocellular carcinoma]. Gastroenterol Clin Biol (2003) 0.75
Insulin-like growth factor 2 gene methylation in peripheral blood mononuclear cells of patients with hepatitis C related cirrhosis or hepatocellular carcinoma. Clin Res Hepatol Gastroenterol (2012) 0.75